[Urticaria … and treatment fails].
According to the guidelines the treatment goal for all types of urticaria is to achieve complete symptom relief. Therefore the available literature for urticaria treatment was reviewed regarding this aim and treatment failure, respectively. Systematic studies are not available. Standard doses of H1-antihistamines are the only approved therapy. Review of the limited data where statements are made about complete alleviation of symptoms shows that standard doses of H1-antihistamines rarely achieve this. Even when the dosage is increased up to four-fold, the failure rate is high. Additional therapy with montelukast, dapsone, and cyclosporine A also often fails to produce complete control. For severe chronic spontaneous urticaria, controlled studies using omalizumab have shown low failure rates over long time periods. It has not been investigated whether up-dosing or reduced injection intervals could further improve this rate. Taken together, the small amount of available data on complete symptom relief in urticaria treatment is astonishing. Moreover, the studies can not be compared due to different inclusion criteria (severity of urticaria, allowed basic treatment) and evaluated parameters. Further controlled studies are vitally needed to achieve the goal of complete symptom relief in urticaria.
Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland, wedi.bettina@mh-hannover.de.
B
B
Wedi
D
D
Wieczorek
U
U
Raap
A
A
Kapp
D003879:Dermatologic Agents / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data*; D015995:Prevalence; D012307:Risk Factors; D017211:Treatment Failure; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control
D003879:Dermatologic Agents; D006635:Histamine H2 Antagonists; D007155:Immunologic Factors; D007166:Immunosuppressive Agents